Commercial cannabidiol oil contaminated with the synthetic cannabinoid AB-FUBINACA given to a pediatric patient

Rianprakaisang, Tony; Gerona, Roy; Hendrickson, Robert G.

doi:10.1080/15563650.2019.1619758

Cited by 18 publications

(9 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As well as cannabinoids, other contaminants have been found in OTC CBD products, including 5F-ADB and AB-FUBINACA, synthetic cannabinoid receptor agonists, 97 , 98 dextromethorphan, an anti-cough medication and dissociative hallucinogen 97 and pesticides. 99 A recent case report described the admission of an otherwise healthy man to an intensive care unit after eating two packets of CBD gummies, although the responsible compound was never identified.…”

Section: Content Of Otc Preparationsmentioning

confidence: 99%

Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products

Chesney

McGuire

Freeman

et al. 2020

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

Over the past 5 years, public interest in the potential health benefits of cannabidiol (CBD) has increased exponentially, and a wide range of over-the-counter (OTC) preparations of CBD are now available. A substantial proportion of the population appears to have used these products, yet the extent to which they are effective or safe is unclear. We reviewed the evidence for whether CBD has significant pharmacological and symptomatic effects at the doses typically found in OTC preparations. We found that most of the evidence for beneficial effects is derived from studies of pure, pharmaceutical grade CBD at relatively high doses. Relatively few studies have examined the effect of OTC CBD preparations, or of CBD at low doses. Thus, at present, there is little evidence that OTC CBD products have health benefits, and their safety has not been investigated. Controlled trials of OTC and low-dose CBD preparations are needed to resolve these issues.

show abstract

Section: Content Of Otc Preparationsmentioning

confidence: 99%

Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products

Chesney

McGuire

Freeman

et al. 2020

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…One consequence of the explosion of public interest in CBD is that a vast array of unregulated products, purporting to contain CBD, are now widely available from online and high-street stores. 96 These products should explicitly not be used for medicinal purposes (for review see Freeman and colleagues) 96 because they are unregulated, not pharmaceutical grade nor produced under good manufacturing practice conditions; 96 their ingredients and dose are uncontrolled, with existing evidence showing that dosage is highly variable and contrary to labelling 97 ; and there is the potential for such products to be contaminated with high levels of other cannabinoids (such as THC), 96–98 which could be detrimental to mental health and especially harmful to those with psychotic disorders. At best, such products represent an expensive placebo due to the typically low doses of CBD per administration (e.g.…”

Section: Cannabidiol In Psychosis: Current Clinical Evidencementioning

confidence: 99%

Cannabidiol as a potential treatment for psychosis

Davies

Bhattacharyya

2019

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

Psychotic disorders such as schizophrenia are heterogeneous and often debilitating conditions that contribute substantially to the global burden of disease. The introduction of dopamine D2 receptor antagonists in the 1950s revolutionised the treatment of psychotic disorders and they remain the mainstay of our treatment arsenal for psychosis. However, traditional antipsychotics are associated with a number of side effects and a significant proportion of patients do not achieve an adequate remission of symptoms. There is therefore a need for novel interventions, particularly those with a non-D2 antagonist mechanism of action. Cannabidiol (CBD), a non-intoxicating constituent of the cannabis plant, has emerged as a potential novel class of antipsychotic with a unique mechanism of action. In this review, we set out the prospects of CBD as a potential novel treatment for psychotic disorders. We first review the evidence from the perspective of preclinical work and human experimental and neuroimaging studies. We then synthesise the current evidence regarding the clinical efficacy of CBD in terms of positive, negative and cognitive symptoms, safety and tolerability, and potential mechanisms by which CBD may have antipsychotic effects.

show abstract

“…In particular, the indazole-3-carboxamide-type SCRAs, are used as street drugs and adulterants in commercial cannabinoid products. For example, MDMB-FUBINACA was identified in e-cigarette liquid ( Peace et al, 2017 ) and AB-FUBINACA was detected in a commercial "cannabidiol oil" administered to a child ( Rianprakaisang et al, 2020 ). Moreover, SCRAs have shown mixed effects on rodent assays used to screen anxiolytic and antidepressant drugs.…”

Section: Introductionmentioning

confidence: 99%

The short-acting synthetic cannabinoid AB-FUBINACA induces physical dependence in mice

Trexler

Vanegas

Poklis

et al. 2020

Drug and Alcohol Dependence

View full text Add to dashboard Cite

Background: Recent years have seen a rise in the diversity and use of synthetic cannabinoids. The present study evaluated the behavioral effects of the third-generation indazole-3-carboxamide-type synthetic cannabinoid, AB-FUBINACA. Methods: Adult male and female C57BL/6J mice were treated with AB-FUBINACA (0–3 mg/kg, i.p.) and tested repeatedly in the tetrad battery measuring catalepsy, antinociception, hypothermia, and locomotor activity. Mice treated with AB-FUBINACA (≥2 mg/kg, i.p.) displayed classic cannabinoid effects in the tetrad that were blocked by the CB 1 receptor selective antagonist rimonabant. To address tolerance and withdrawal effects, a second group of mice was injected with AB-FUBINACA (3 mg/kg, s.c.) or vehicle consisting of 5% ethanol, 5% Kolliphor EL, and 90 % saline every 12 h and tested daily in modified tetrad over the course of 5 days. On the 6th day, withdrawal was precipitated using rimonabant (3 mg/kg, s.c.), and somatic signs of withdrawal (i.e., head twitches and paw tremors) were quantified. Results: Although mice did not develop tolerance to AB-FUBINACA or cross-tolerance to Δ 9 -tetrahydrocannabinol (THC; 50 mg/kg, i.p.), somatic precipitated withdrawal signs were observed. Repeated tetrad testing up to 48 h post injection indicated that AB-FUBINACA effects are relatively short-lived, as compared with THC. Brain levels of AB-FUBINACA, as quantified by UHPLC-MS/MS, were undetectable 4 h post injection. Conclusions: These data indicate that the cannabinoid effects of AB-FUBINACA are relatively short-lived, yet sufficient to induce dependence in mice.

show abstract

Commercial cannabidiol oil contaminated with the synthetic cannabinoid AB-FUBINACA given to a pediatric patient

Cited by 18 publications

References 3 publications

Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products

Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products

Cannabidiol as a potential treatment for psychosis

The short-acting synthetic cannabinoid AB-FUBINACA induces physical dependence in mice

Contact Info

Product

Resources

About